|View printer-friendly version|
|Avinger Provides Update on U.S. Intellectual Property Portfolio|
The U.S. Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 9,854,979, titled “Chronic Total Occlusion Crossing Devices with Imaging.” In addition, the USPTO has provided an Issue Notification for U.S. Patent Application No. 13/752,325, titled “Catheter System and Method for Boring Through Blocked Vascular Passages,” which is expected to issue as U.S. Patent No. 9,918,734 on March 20, 2018 and has provided a Notice of Allowance for certain claims in U.S. Patent Application No. 14/433,786, titled “Occlusion-Crossing Devices.”
All three of these patents relate to Avinger’s portfolio of technologies used for crossing completely blocked arteries, also referred to as chronic total occlusions or CTOs, in both the peripheral and coronary arteries. The Company’s Ocelot device is the only image-guided CTO-crossing catheter cleared for sale in the U.S. by the
“These positive actions by the USPTO help to establish Avinger’s technology leadership in the field of CTO crossing,” commented
Avinger’s extensive intellectual property portfolio now includes 119 patents and applications, including 19 issued and allowed U.S. cases, 23 pending U.S. applications, 29 issued and allowed cases outside the U.S., and 48 pending applications outside the U.S. The portfolio has broad applicability in the areas of atherectomy, CTO-crossing and intravascular imaging.
Public Relations Contact